BioCentury | Aug 28, 2020
Finance

Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence

...Burton & Co. and the Montreal-based Centre for Commercialization of Cancer Immunotherapy (C3i). Oceanpine Capital and Viva Biotech...
BioCentury | May 14, 2020
Finance

May 13 Quick Takes: MyoKardia raises $551M; plus Legend looks to NASDAQ for IPO and ADC, Travecta, QureBio, Kintor, Lantern, Kiromic

...has raised tens of millions in an A+ round from Shenzhen Capital Group. Incubated by Viva Biotech...
BioCentury | Mar 26, 2020
Finance

March 25 Quick Takes: Temasek leads Abbisko’s $70M C round; plus IASO and Regenacy

...Cobro Ventures and Taiwania Capital Management Corp., with participation from 3E Bioventures Capital, Yonjin Capital, Viva Biotech...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:NXTC) 5/8/19 $86.3 $340.3 $340.3 0% Axcella Health Inc. (NASDAQ:AXLA) 5/8/19 $71.4 $459.8 $214.2 -53% Viva Biotech...
BioCentury | May 9, 2019
Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

...it ended the week down 17% from its listing price. Meanwhile in Hong Kong, CRO Viva Biotech...
BioCentury | May 8, 2019
Financial News

CRO Viva raises $193.9 million in Hong Kong IPO

...in an IPO that values the drug discovery services company at HK$6.6 billion (US$843.1 million). Viva Biotech...
...Biopharm Co. Ltd. (Suzhou, China). -Assistant Editor Paul Bonanos contributed to this report. Hongjiang Li, Staff Writer Viva Biotech...
BioCentury | Apr 26, 2019
Financial News

CRO Viva could get $749M valuation in Hong Kong listing, Ascentage refiles

...prices its Hong Kong IPO at the midpoint of the range it proposed April 25. Viva Biotech...
...the Hong Kong stock exchange. The company proposed the listing in July 2018 (see "CRO Viva Biotech...
...lapse (see "Ascentage Hops in Hong Kong IPO Queue" ). Hongjiang Li, Staff Writer Ascentage Pharma Group International Viva Biotech...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...HKEX) 8/22/18 TBD Ph III (biosimilar) Ascentage Pharma Group International (HKEX) 8/20/18 TBD Ph II/III Viva Biotech...
BioCentury | Aug 4, 2018
Finance

Hong Kong’s first wave

...time of filing; Source: BCIQ: BioCentury Online Intelligence, HKEX website Company Date filed Status (A) Viva Biotech...
BioCentury | Jul 27, 2018
Financial News

CRO Viva Biotech proposes HKEX listing

...in exchange for 10% to 30% equity in an equity-for-service model. Viva Biotech Holdings, Shanghai, China Alicia Parker Viva Biotech...
Items per page:
1 - 10 of 11
BioCentury | Aug 28, 2020
Finance

Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence

...Burton & Co. and the Montreal-based Centre for Commercialization of Cancer Immunotherapy (C3i). Oceanpine Capital and Viva Biotech...
BioCentury | May 14, 2020
Finance

May 13 Quick Takes: MyoKardia raises $551M; plus Legend looks to NASDAQ for IPO and ADC, Travecta, QureBio, Kintor, Lantern, Kiromic

...has raised tens of millions in an A+ round from Shenzhen Capital Group. Incubated by Viva Biotech...
BioCentury | Mar 26, 2020
Finance

March 25 Quick Takes: Temasek leads Abbisko’s $70M C round; plus IASO and Regenacy

...Cobro Ventures and Taiwania Capital Management Corp., with participation from 3E Bioventures Capital, Yonjin Capital, Viva Biotech...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:NXTC) 5/8/19 $86.3 $340.3 $340.3 0% Axcella Health Inc. (NASDAQ:AXLA) 5/8/19 $71.4 $459.8 $214.2 -53% Viva Biotech...
BioCentury | May 9, 2019
Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

...it ended the week down 17% from its listing price. Meanwhile in Hong Kong, CRO Viva Biotech...
BioCentury | May 8, 2019
Financial News

CRO Viva raises $193.9 million in Hong Kong IPO

...in an IPO that values the drug discovery services company at HK$6.6 billion (US$843.1 million). Viva Biotech...
...Biopharm Co. Ltd. (Suzhou, China). -Assistant Editor Paul Bonanos contributed to this report. Hongjiang Li, Staff Writer Viva Biotech...
BioCentury | Apr 26, 2019
Financial News

CRO Viva could get $749M valuation in Hong Kong listing, Ascentage refiles

...prices its Hong Kong IPO at the midpoint of the range it proposed April 25. Viva Biotech...
...the Hong Kong stock exchange. The company proposed the listing in July 2018 (see "CRO Viva Biotech...
...lapse (see "Ascentage Hops in Hong Kong IPO Queue" ). Hongjiang Li, Staff Writer Ascentage Pharma Group International Viva Biotech...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...HKEX) 8/22/18 TBD Ph III (biosimilar) Ascentage Pharma Group International (HKEX) 8/20/18 TBD Ph II/III Viva Biotech...
BioCentury | Aug 4, 2018
Finance

Hong Kong’s first wave

...time of filing; Source: BCIQ: BioCentury Online Intelligence, HKEX website Company Date filed Status (A) Viva Biotech...
BioCentury | Jul 27, 2018
Financial News

CRO Viva Biotech proposes HKEX listing

...in exchange for 10% to 30% equity in an equity-for-service model. Viva Biotech Holdings, Shanghai, China Alicia Parker Viva Biotech...
Items per page:
1 - 10 of 11